<DOC>
	<DOCNO>NCT00868374</DOCNO>
	<brief_summary>The primary objective test hypothesis quetiapine XR ( Extended Release ) monotherapy adjunctive therapy antidepressant superior placebo monotherapy placebo adjunctive therapy antidepressant ( ) acute treatment depression symptom patient MDD comorbid GAD . The secondary objective test hypothesis quetiapine XR superior placebo reduction anxiety symptom patient major depressive disorder comorbid generalize anxiety disorder , improvement quality sleep patient major depressive disorder comorbid generalize anxiety disorder improvement quality life patient major depressive disorder comorbid generalize anxiety disorder .</brief_summary>
	<brief_title>Quetiapine Extended Release ( XR ) Treatment Major Depressive Disorder With Comorbid Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Able provide inform consent begin studyspecific procedure Male female patient least 18 year age 70 year age Meets Diagnostic Statistical Manual IV ( DSMIV ) criterion MDD , currently depress DSMIV diagnosis current GAD Women reproductive potential must negative urine pregnancy test Patients current episode depression le 4 week enrollment Patients treat current depressive episode 3 week Quetiapine therapy 50 mg/day Patients currently take antidepressant know cause somnolence/sedation mirtazapine unable wean current antidepressant choose monotherapy Patients meet DSMIV criterion substance dependence confirm Substance Use Disorder Module Structured Clinical Interview DSMIV ( SCID ) , substance except caffeine nicotine , substance abuse within last 3 month substance dependence within last 6 month ; Concurrent obsessivecompulsive disorder Patients history clinically significant cardiac , renal , neurologic , cerebrovascular , metabolic , pulmonary disease , disease clinical finding unstable , opinion investigator , would negatively effect trial medication would effect trial medication A patient diabetes mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrollment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % Admitted hospital treatment DM DM relate illness within past 12 week Not physician care DM Physician responsible patient 's DM care indicate patient 's DM control Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycemic drug ( ) and/or diet 4 week randomization ( thiazolidinediones ( glitazones ) period le 8 week randomization ) Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If patient DM meet one criterion , patient exclude even treat physician believe patient stable participate study . A patient could enrol later time DM stabilize .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>